Boston Bio Systems Ltd.
CIN No. L31100GJ995PLC25476 Reg No. 25476
www.bostonbio.in bostonsystem@yahoo.com

14TH JANUARY, 2024

BSE Limited,
Phiroze Jeejeebhoy Tower,
Dalal Street,
Mumbai - 400001.

SCRIPT CODE: 531458

Sub: Outcome of the Board of Directors meeting held today i.e. 14th January, 2024, as per Regulations 30 and 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulation")

Dear Sir/ Madam,

We wish to inform you that the Board of Directors of the Company has considered and approved inter-alia the following matter in their meeting held today i.e. 14th January, 2024 commenced at 2:00 P.M. and concluded at 3:30 PM:

1. **Approval of Unaudited Financial results for the 3rd Quarter ended 31st December, 2023**

The Board has approved the Un-Audited Financial Results (Standalone) for the 3rd quarter ended 31st December, 2023 (F.Y. 2023-24) along with the Limited Review Report of the Auditors. The said results have been reviewed by the audit Committee and approved by the Board of Directors of the Company are enclosed

Please take above in your record

Thanking You,

Yours Faithfully,

For and on behalf of
Boston Bio Systems Limited

Kushal Rathore
Director
DIN: 06493647

BOSTON BIO SYSTEMS LIMITED

CIN: L31100GJ1995PLC025476

Registered Office: 17/B, 4th Floor,Sandesh Commercial Complex, Old Madhuram Cinema, Mirzapur Ahmedabad, Gujarat-380001, India

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Rs. In lakhs)

Sl. No.	Particulars	Quarter ended		Nine months ended		Year ended	
		31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
		Audited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Income						
	a) Revenue from operations	-	-	-	-	-	-
	b) Other income	-	-	-	-	-	-
	Total income	-	-	-	-	-	-
2	Expenses						
	a) Purchase of stock in trade	-	-	-	-	-	-
	b) Changes in inventories of stock in trade	-	-	-	-	-	-
	c) Employee benefits expense	-	-	-	-	-	-
	d) Finance costs	-	-	-	-	-	-
	e) Depreciation and amortisation expense	-	-	-	-	-	-
	f) Other expenses	-	-	-	-	-	0.22
	Total expenses	-	-	-	-	-	0.22
3	Profit / (Loss) before exceptional Items and tax (1-2)	-	-	-	-	-	(0.22)
4	Exceptional items	-	-	-	-	-	-
5	Profit / (Loss) before tax (3-4)	-	-	-	-	-	(0.22)
6	Tax expense						
	a) Current tax	-	-	-	-	-	-
	b) Deferred tax	-	-	-	-	-	-
7	Profit / (Loss) after Tax (5-6)	-	-	-	-	-	(0.22)
8	Other comprehensive income						
	a) Items that will not be reclassified to profit and loss	-	-	-	-	-	-
	Re-measurement gains (losses) on defined benefit plans	-	-	-	-	-	-
	Income tax effect	-	-	-	-	-	-
	b) Income tax relating to items that will not be reclassified to profit and loss	-	-	-	-	-	-
	Net other comprehensive income to be reclassified to profit or loss in subsequent periods	-	-	-	-	-	-
	Income tax effect	-	-	-	-	-	-
	Total other comprehensive income / (loss) for the year	-	-	-	-	-	-
9	Total comprehensive income / (loss) for the period/year (7+8)	-	-	-	-	-	(0.22)

MAHAR V. & CO. JAORA (M.P.) CHARTERED ACCOUNTANTS

10	Paid up equity share capital (face value of Rs. 10 per share)	**700.22**	**700.22**	**700.22**	**700.22**	**700.22**	**700.22**
11	Other equity (Reserve excluding revaluation reserves)	-	-	-	-	-	(40.97)
12	**Earnings per equity share (face value of Rs. 10 per share)**						
	Basic (Rs.)	-		-	-	-	(0.00)
	Diluted (Rs.)	-		-	-	-	(0.00)

Note:

1. The unaudited standalone financial results have been reviewed and approved by the board of directors at their meeting held on 14th January, 2024. In compliance with the securities and exchange board of India (Listing Obligations and Disclosure Requirements) Regulations as amended, 2015 ("SEBI Listing Regulations"), a A115 limited review of the above results has been carried out by the statutory auditors of the company.

2. The unaudited standalone financial results have been prepared in accordance with the Indian Accounting Standards (Ind AS), Section 133 of the Companies Act, 2013 read with rules framed thereunder and Schedule III to the Companies Act, 2013 as amended.

3. The company has a single reportable segment for the purpose of Ind AS-108.

For and on behalf of the Board of Directors
For BOSTON BIO SYSTEMS LIMITED

NAHAR V. & CO. JAORA (M.P.) CHARTERED ACCOUNTANTS

Kushal Rathore
Director
DIN:06493647

Place: Gujarat
Date: 14.01.2024

Nahar V. & Company
CHARTERED ACCOUNTANTS
CA Vishal Nahar
B.Com., F.C.A., DISA (I.C.A.I.)
12, Bajaj Khana, JAORA ; Dist. Ratlam
☎ : 07414-221253, 222652
Mob. 98272 73710, Fax : 0731-2577943
E-mail : vnaharin@yahoo.com

Ref.

Date :

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results to Standalone Unaudited Year to Date Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

Review Report to
The Board of Directors
Boston Bio Systems Limited

1. We have reviewed the accompanying Statement of Standalone Unaudited Financial Results ("Statement") of **Boston Bio Systems Limited** ("the Company") for the quarter ended 31st December 2023 and the Standalone Unaudited year to date results for the period 1 April 2023 To 31st December 2023 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI ((Listing Obligations and Disclosure Requirements) Regulation, 2015 (the "Regulation") as amended, including relevant circulars issued by the SEBI from time to time.

2. This statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related audited interim standalone financial information which has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" (Ind AS 34), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express an opinion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statements are free of material misstatements. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

NAHAR V. & CO. JAORA (M.P.) CHARTERED ACCOUNTANTS

4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards 34 (Ind AS-34) specified under section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of the Regulation, read with circular, including the manner in which it is to be disclosed, or that it contains any material misstatement

For **Nahar V& Company**
Chartered Accountants
Firm Registration No. 010443C

NAHAR V. & CO. JAORA (M.P.) CHARTERED ACCOUNTANTS

Vishal Nahar
Proprietor
M. No.: 400217
UDIN : 24400217BKAQUO5174

Place: Indore
Date: 14.01.2024